CD19/CD22-bispecific CAR-T / Beijing Tongren Hospital - LARVOL DELTA

CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory large B-cell lymphoma: A prospective, single-arm, single-center, phase II clinical trial (ESMO 2025) - P2 | "This trial is still ongoing. ( NCT06081478)."

CAR T-Cell Therapy • Clinical • P2 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy. (PubMed, J Immunother Cancer) - "We acknowledge that this case lies on a spectrum between clonal lymphoproliferative disorder and overt PTCL, and terminology continues to evolve. This case suggests a need for re-biopsy of suspected relapses after CAR-T therapy and highlights the limitations of conventional product assessment in detecting premalignant clones."

IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CBX5 • CD22 • NF1 • TET2

MAINTENANCE THERAPY WITH PD-1 INHIBITOR AND SELINEXOR FOLLOWING CD19/CD22 BISPECIFIC CAR-T CELL THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS (EHA 2026) - P2 | "The maintenance regimen consisted of PD-1 inhibitor (tislelizumab 200 mg or serplulimab 240 mg intravenously every 3 weeks) plus selinexor (40-60 mg orally once weekly) for 1-2 years duration. The observed reduction in PD-1+ T-cells supports an immunomodulatory mechanism of action. These findings warrant further investigation in prospective randomized trials to establish the optimal maintenance strategy post-CAR-T therapy."

Bispecific • CAR T-Cell Therapy • IO biomarker • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD22 • XPO1

SECONDARY PERIPHERAL T-CELL LYMPHOMA IN A PATIENT OF DLBCL HARBORING CANCER SUSCEPTIBILITY GENE MUTATION FOLLOWING CD19/CD22 BISPECIFIC CAR-T CELL THERAPY (EHA 2026) - "These findings underscore the critical importance of pre-infusion genomic screening of CAR-T products for CHIP-related mutations, cancer susceptibility gene testing in patients with prior malignancies, and lifelong surveillance for secondary malignancies in CAR-T recipients. ."

Bispecific • CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Cervical Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CBX5 • CD22 • KMT2A • NF1 • TET2

CD19/CD22 BISPECIFIC CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND MECHANISTIC INVESTIGATION: A PROSPECTIVE, SINGLE-ARM, SINGLE-CENTER, PHASE 2 CLINICAL TRIAL (EHA 2026) - P2 | "A 3-day lymphodepletion (cyclophosphamide: 250 mg/m2/d; fludarabine: 25 mg/m2/d) was followed by an intravenous dose of CAR2219 (2×10e6/kg)...Tocilizumab and corticosteroids were effective in managing CRS and ICANS, and no treatment-related deaths were reported...Enrichment of specific CD4 ⁺ T cell subsets, activation of the interferon pathway, and activation of viral mimicry may be closely associated with the efficacy of this therapy. (ClinicalTrials.gov Identifier: NCT06081478)"

Bispecific • CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD22 • CD4 • DDX58

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: Beijing Tongren Hospital | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2026 ➔ Apr 2026

Enrollment closed • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Beijing Tongren Hospital

New P2 trial • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study (ASH 2025) - "Current combination strategies aim to enhance the efficacy of CAR-T therapy,with selinexor emerging as a promising candidate.Patients and A retrospective, single-center, real-world study was conducted to assess theefficacy and safety of selinexor in combination with CD19/CD22 bispecific CAR-T cell therapy in patientswith relapsed/refractory DLBCL. Our findings indicate that the addition of selinexor as bridging therapy may enhancetreatment strategies for patients undergoing CAR T-cell therapy. However, extended follow-up isnecessary to confirm the long-term therapeutic benefits of this combined regimen."

Combination therapy • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD22 • XPO1

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial (ASH 2025) - P2 | "A 3-day lymphodepletion (cyclophosphamide: 250mg/m2/d; fludarabine: 25 mg/m2/d) was followed by an intravenous dose of CAR2219 (2×10e6/kg)...Tocilizumab and corticosteroids were effective in managing CRS and ICANS, and no treatment-related deaths were reported... CD19/CD22 bispecific CAR-T cell therapy demonstrated impressive efficacy and a favorablesafety profile in patients with R/R LBCL. This trial is still ongoing. (ClinicalTrials.gov Identifier:NCT06081478)"

CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD22

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma (ASH 2024) - P2 | "At the time of enrollment to this clinical trial of CD19/CD22 bispecific CAR-T cell therapy, eight patients had stage III-IV disease, and the median IPI score was four (1-5)...All patients completed one cycle of MPD with/without rituximab...All patients successfully proceeded to subsequent lymphodepleting therapy.Conclusions : MPD regimen was highly effective and well tolerated in patients with R/R-DLBCL who meant to receive CAR-T cell therapy, and could be used as bridging therapy to control disease and improve performance status to facilitate subsequent CAR-T infusion. Well-designed prospective clinical trials are needed to confirm our findings."

CAR T-Cell Therapy • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD22

CD19/CD22 BISPECIFIC CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, SINGLE-CENTER, PHASE 2 CLINICAL TRIAL (ICML 2025) - P2 | "A 3-day lymphodepletion (cyclophosphamide: 250 mg/m2/d; fludarabine: 25 mg/m2/d) was followed by an intravenous dose of CAR2219 (2 × 10e6/kg)...Tocilizumab and corticosteroids were effective in managing CRS and ICANS, and no treatment-related deaths were reported... CD19/CD22 bispecific CAR-T cell therapy demonstrated significant efficacy and a favorable safety profile in patients with R/R LBCL, particularly in addressing antigen escape and enhancing long-term remission rates. This trial is still ongoing (ClinicalTrials.gov Identifier: NCT06081478)."

CAR T-Cell Therapy • Clinical • P2 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

CD19/CD22 BISPECIFIC CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, SINGLE-CENTER, PHASE 2 CLINICAL TRIAL (EHA 2025) - P2 | "A 3-day lymphodepletion (cyclophosphamide: 250 mg/m2/d; fludarabine: 25 mg/m2/d) was followed by an intravenous dose of CAR2219 (2×10e6/kg)...Tocilizumab and corticosteroids were effective in managing CRS and ICANS, and no treatment-related deaths were reported... CD19/CD22 bispecific CAR-T cell therapy demonstrated significant efficacy and a favorable safety profile in patients with R/R LBCL, particularly in addressing antigen escape and enhancing long-term remission rates. This trial is still ongoing. (ClinicalTrials.gov Identifier: NCT06081478)"

CAR T-Cell Therapy • Clinical • P2 data • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD22